Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitor

This page shows the latest PD-L1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Bad news for BMS as Keytruda kidney cancer combo approved

Bad news for BMS as Keytruda kidney cancer combo approved

The Keytruda duo also cut the risk of death by 46% with those carrying the PD-L1 biomarker – and in 41% of those without. ... However, it was forced to withdraw that application, allowing Keytruda to lead the charge, as the PD-1/PD-L1 inhibitor market

Latest news

  • Chi-Med goes for third IPO in Hong Kong Chi-Med goes for third IPO in Hong Kong

    combination with the latter’s EGFR inhibitor Tagrisso (osimertinib) and PD-L1 checkpoint inhibitor Imfinzi (durvalumab) in a series of proof-of-concept trials in solid tumours. ... It is in a clutch of trials as a monotherapy in neuroendocrine tumours

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    BMS ran into a hurdle with this combo earlier this year however, and pulled the marketing application in the US after the FDA requested for more information on TMB, PD-L1 ... expression and overall survival rates, casting a cloud over PD-L1 checkpoint

  • Celgene’s Abraxane fails pancreatic cancer trial Celgene’s Abraxane fails pancreatic cancer trial

    It secured another this week when the FDA cleared the drug in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) for triple-negative breast cancer – becoming the first immunotherapy regimen

  • AZ signs $20m deal with Seres for microbiome project AZ signs $20m deal with Seres for microbiome project

    of Seres’ microbiome candidates – SER-401 – tested in combination with AZ’s cancer therapies including its PD-L1 checkpoint inhibitor Imfinzi (durvalumab). ... Preclinical and early clinical evidence suggests that the composition of the

  • More good news, and some bad, for Merck’s Keytruda More good news, and some bad, for Merck’s Keytruda

    It’s the second priority review filing for Keytruda to get underway at the FDA in a week, coming after the PD-1 inhibitor was filed as a first-line treatment ... The rare setback for Keytruda comes as it has started to show signs of lengthening its new

More from news
Approximately 4 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... This deal gives Pfizer co-development and co-marketing rights to MSB0010718C, Merck KGaA's anti-PD-L1

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Investing in our People
As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....
Body image and mental health: The psoriasis connection
As part of mental health awareness week, the Mental Health Foundation (MHF) have released a new report on the interaction between body image and mental health. Our Medical Writer Alex...
It’s not the end of the world, is it?
Industry change isn’t always gradual – it can be apocalyptic...

Infographics